On-line version ISSN 2078-5151
S. Afr. j. surg. vol.48 n.4 Cape Town Nov. 2010
S. W. MooreI; M. G. ZaahlII
IM.B. Ch.B., F.R.C.S. (edin.), M.D.; Division of Paediatric Surgery, Department of Surgical Sciences, Stellenbosch University, Tygerberg, W Cape
IIPh.D.; Department of Genetics, Stellenbosch University
The RET proto-oncogene (REarranged during Transfection; RET) plays an important role in the causation of many thyroid tumours. Germline RET proto-oncogene missense mutations have been clearly linked to medullary thyroid carcinoma (MTC) and the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN2A, MEN2B).
METHODS: We investigated a cohort of MEN2-related patients referred to Tygerberg Hospital, W Cape (2003 -2009). The study cohort was divided into three groups based on pathology (viz. MEN/MTC, phaeochromocytoma, and a miscellaneous group of MEN pathologies). Families with identified high-risk factors were recalled. Serum calcitonin levels were monitored where indicated.
DNA was extracted from whole blood by standard techniques and polymerase chain reaction (PCR) products screened for RET gene variations by heteroduplex singlestrand duplication techniques (heteroduplex single-strand conformation polymorphism analysis) being validated with automated sequencing techniques showing conformational variants in acrylamide gel.
RESULTS: We screened 40 persons, male/female ratio 1:1.5. Three ethnic groups were represented (white (12), black (11) and mixed race (17)). Nine were index MTC cases, 5 phaeochromocytoma, 3 Hirschsprung's disease-MEN associations and 2 miscellaneous (1 neuroblastoma, 1 intestinal neuronal dysplasia], while 1 fell into the MEN2B category. The remaining 19 were unaffected relatives screened for carrier status, among whom a familial recurrence was observed in 7.
On genetic testing, an RET point mutation at the high-risk 634 cysteine allele was identified in 11 cases. A further cysteine radical mutation at the 620 position was related to MEN2 in 3 families plus 1 other family referred from elsewhere. Other less-recognised gene variations were detected throughout the RET gene in 70% of cases and included the 691 position on codon 11 (11 cases); the 432 position (4 cases, 1 homozygous) intronic mutations on exon 4 (1 case); and an IVS19-37G/C and a D1017N variation in exon 19 in 2 MEN families.
Fifteen MTC patients have had thyroidectomies, of which 2 were prophylactic (C-cell hyperplasia; early occult MTC). A further 3 are awaiting prophylactic surgery.
CONCLUSION: RET gene mutation carries a risk of MEN2 and MTC in all ethnic groups in South Africa. Prophylactic surgery may prevent MTC, so genetic screening is important to identify and treat high-risk patients.
“Full text available only in PDF format”
1. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973 - 1991. Cancer 1997; 79(3): 564-573. [ Links ]
2. Kebebew E, Clark OH. Medullary thyroid cancer. Curr Treat Options Oncol 2000; 1(4): 359-367. [ Links ]
3. Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458-460. [ Links ]
4. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2(7): 851-856. [ Links ]
5. Van Heyningen V. Genetics. One gene - four syndromes. Nature 1994; 367: 319320. [ Links ]
6. Wells SA Jr, Santoro M. Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009; 15: 7119-7123. [ Links ]
7. Borrego S, Eng C, Sanchez B, et al. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab 1998; 83(9): 3361-3364. [ Links ]
8. Fitze G, Saeger HD, Roesner D, Schackert HK. Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene. Klin Padiatr 2004; 216(5): 270-276. [ Links ]
9. Gimm O, Ukkat J, Niederle BE, et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004; 28(12): 1312-1316. [ Links ]
10. Gimm O, Neuberg DS, Marsh DJ, et al. Over representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 1999; 18: 1369-1373. [ Links ]
11. Unruh A, Fitze G, Janig U, et al. Medullary thyroid carcinoma in a 2-month-old male with multiple endocrine neoplasia 2B and symptoms of pseudo-Hirschsprung disease: a case report. J Pediatr Surg 2007; 42(9): 1623-1626. [ Links ]
12. Machens A, Holzhausen HJ, Thanh PN, Dralle H. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 2003; 134(3): 425-431. [ Links ]
13. Zenaty D, Aigrain Y, Peuchmaur M, et al. Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. Eur J Endocrinol 2009; 160 (5): 807-813. [ Links ]
14. Machens A, Ukkat J, Brauckhoff M, et al. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005; 257(1): 50-59. [ Links ]
15. Han Z, Qiu C, Chen Q, Zhu Y, et al. Mutation screening of RET proto-oncogene in Chinese sporadic patients with pheochromocytoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006; 23(3): 320-322. [ Links ]
16. Garcia-Barcelo M, Sham MH, Lee WS, et al. Highly recurrent RET mutations and novel mutations in genes of the receptor tyrosine kinase and endothelin receptor B pathways in Chinese patients with sporadic Hirschsprung disease. Clin Chem 2004; 50(1): 93-100. [ Links ]
17. Julies MG, Moore SW, Kotze MJ, du Plessis L. Novel RET mutations in Hirschsprung's disease patients from the diverse South African population. Eur J Hum Genet 2001; 9: 419-423. [ Links ]
18. Ceccherini I, Hofstra RM, Luo Y, et al. DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 1994; 9: 3025-3029. [ Links ]
19. Kotze M, Theart L, Callis M, Peeters A, et al. Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low-density lipoprotein receptor gene mutations. PCR Methods Applic 1995; 4: 352-356. [ Links ]
20. Moore SW, Zaahl M. Familial associations in medullary thyroid carcinoma with Hirschsprung's disease: the role of the RET C620 'Janus' genetic variation. J Pediatr Surg 2010; 45: 393-396. [ Links ]
21. Russo A, Zanna I, Tubiolo C, et al. Hereditary common cancers: molecular and clinical genetics. Anticancer Res 2000; 20(6C): 4841-4851. [ Links ]
22. Knowles PP, Murray-Rust J, Kjaer S, et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 2006; 281(44): 33577-33587. [ Links ]
23. Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet1994; 6(1): 70-74. [ Links ]
24. Borrello MG, Smith DP, Pasini B, et al. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995; 11(11): 2419-2427. [ Links ]
25. Carlomagno F, Salvatore G, Cirafici AM, et al. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 1997; 57: 391-395. [ Links ]
26. Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: Oncological features and biochemical properties. J Clin Endocrinol Metab 2001; 86(3): 1104-1109. [ Links ]
27. Machens A, Brauckhoff M, Holzhausen HJR, et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 2005; 90(7): 3999-4003. [ Links ]
28. Machens A, Dralle, H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 2007; 31: 957-968. [ Links ]
29. Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 1998; 7(1): 129-134. [ Links ]
30. Butter A, Gagne J, Al Jazaeri A, et al. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. J Pediatr Surg 2007; 42(1): 203-206. [ Links ]
31. Frank-Raue K, Buhr H, Dralle H, et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 2006; 155(2): 229-236. [ Links ]
32. Torre M, Martucciello G, Ceccherini I, et al. Diagnostic and therapeutic approach to multiple endocrine neoplasia type 2B in pediatric patients. Pediatr Surg Int 2002; 18(5-6): 378-383. [ Links ]
33. Carlson KM, Bracamontes J, Jackson CE, et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 1994; 55(6): 1076-1082. [ Links ]
34. Sanso GE, Domene HM, Garcia R, et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 2005; 94(2): 323-330. [ Links ]
35. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990; 60: 557-563. [ Links ]
36. Rabes HM, Klugbauer S. Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement. Recent Results Cancer Res 1998; 154: 248-264. [ Links ]
37. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995; 15(3): 1613-1619. [ Links ]
38. Santoro M, Grieco M, Melillo RM, et al. Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 1995; 133(5): 513-522. [ Links ]
39. Salvatore D, Melillo RM, Monaco C, et al. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B. Cancer Res 2001; 61(4): 1426-1431. [ Links ]
40. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004; 204(2): 197-211. [ Links ]
41. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003; 349(16): 1517-1525. [ Links ]
42. Schellhaas E, Konig C, Frank-Raue K, et al. Long-term outcome of 'prophylactic therapy' for familial medullary thyroid cancer. Surgery 2009; 146: 906-912. [ Links ]
43. Machens A, Holzhausen HJ, Dralle H. Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: systemic disease? Surgery 2006; 139(1): 28-32. [ Links ]
44. Wells SA, Nevins JR. Evolving strategies for targeted cancer therapy - past, present, and future. J Natl Cancer Inst 2004; 96(13): 980-981. [ Links ]